噬菌体疗法治疗人类肌肉骨骼与皮肤软组织感染
本文为叙述性综述,检索PubMed与Clinicaltrials.gov,评估噬菌体疗法用于人类肌肉骨骼、皮肤及软组织感染的历史与当前数据,并梳理已注册临床试验。噬菌体疗法似乎安全且临床结果有前景,但受监管障碍限制,多限于同情用药或临时批准,尚需高质量随机对照试验数据。
要点
- 噬菌体疗法在肌肉骨骼与皮肤软组织感染中应用历史悠久,因抗菌药物耐药上升而重新受到关注。
- 目前噬菌体治疗用途受监管障碍限制,在欧洲和美国多限于同情用药授权或作为新药临时批准。
- 噬菌体疗法似乎安全且临床结果有前景,尚需高质量随机对照试验数据以明确扩展应用的合理最低标准。
核心结论
- 噬菌体疗法似乎安全且噬菌体治疗的临床结果有前景,未来高质量随机对照试验数据可更好地理解扩展噬菌体疗法所需的合理最低标准。
研究设计与样本
- 叙述性综述,检索PubMed与Clinicaltrials.gov,检索词为「bacteriophage therapy」「musculoskeletal infection」「soft tissue infection」,并核查所有检索文献的参考文献以补充相关文献。
主要发现
- 噬菌体疗法在肌肉骨骼与皮肤软组织感染中应用历史悠久,尤其在苏联时期。
- 由于全球抗菌药物耐药上升,噬菌体应用兴趣复苏并扩展至许多国家。
- 目前噬菌体治疗用途受监管障碍限制,在欧洲和美国多限于同情用药的零星授权或作为新药临时批准。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bacteriophage therapy has a long history in the treatment of musculoskeletal and skin/soft tissue infections, particularly in the former Soviet Union. Due to the global rise in antimicrobial resistance, phage application has experienced a resurgence of interest and expanded to many countries. OBJECTIVES: This narrative review aims to provide clinical microbiologists, infectious disease specialists and surgeons a brief history of bacteriophage therapy for human musculoskeletal and soft tissue infections, as well as data on current practices and ongoing clinical studies. SOURCES: A search of PubMed and Clinicaltrials.gov was performed to identify relevant studies. Search terms were 'bacteriophage therapy', 'musculoskeletal infection' and 'soft tissue infection'. The bibliography of all retrieved articles was checked for additional relevant references. CONTENT: Past and current data on the use of bacteriophage therapy for human musculoskeletal, skin and soft tissue infections are evaluated. Moreover, we present the clinical trials registered in public databases. Based on current clinical experience and data, several scenarios of bacteriophage application for human therapy are examined. Finally, we discuss legislative hurdles in the regulatory approval process and present future perspectives for bacteriophage therapy. IMPLICATIONS: Antimicrobial resistance is one of the most important global public health challenges. Several different alternatives to conventional antibiotics are under development; bacteriophage therapy is one of them. Currently, therapeutic use of phages is restrained by regulatory hurdles and largely limited to sporadic authorization in compassionate use or under temporary approval as new drugs in Europe and the US. Although bacteriophage therapy seems to be safe and clinical results of phage treatment are promising, future data from high-quality (randomized controlled) trials could provide a better understanding of the reasonable minimal criteria required for expansion of bacteriophage therapy.
引用
- Metsemakers WJ, Onsea J, Moriarty TF, et al. Bacteriophage therapy for human musculoskeletal and skin/soft tissue infections. Clin Microbiol Infect. 2023. PMID: 36669559. doi:10.1016/j.cmi.2023.01.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。